pathogen
infect
viru
requir
subunit
spike
protein
bind
host
cell
receptor
angiontensin
convert
enzym
bind
host
cell
receptor
first
step
infect
entranc
viru
cell
need
cleavag
subunit
expos
fusion
cell
membran
via
host
proteas
includ
cathepsin
cell
surfac
transmembran
proteaseserin
tmprss
proteas
furin
trypsin
factor
xa
previou
vitro
studi
shown
factor
xa
inhibit
decreas
viral
infect
suppos
host
cell
proteas
includ
furin
express
highli
lung
factor
xa
cathepsin
possibl
target
decreas
viral
burden
therefor
unfract
heparin
low
molecular
weight
heparinlmwh
specif
dalteparin
tinzaparin
anti
inflammatori
action
potenti
inhibitor
multipl
endoproteas
involv
viru
infect
hypothesi
need
test
vitro
clinic
studi
howev
urgent
situat
burden
increas
around
world
recommend
usag
unfract
heparin
lmwh
intens
care
unit
icu
nonicu
hospit
patient
riskbenefit
judgement
clinician
whether
hypothesi
clinic
applic
success
decreas
viral
infect
evalu
studi
current
world
face
novel
coronaviru
outbreak
tremend
effort
made
develop
drug
treat
vaccin
prevent
diseas
present
march
paper
written
specif
antivir
drug
vaccin
although
patient
develop
mild
diseas
patient
includ
higher
age
patient
comorbid
like
hypertens
diabet
mellitu
chronic
obtsruct
pulmonari
diseas
although
pathogen
pathway
fulli
understood
know
share
similar
sarscov
hypothes
offer
treament
option
origin
sarscov
pathogenesi
singl
strand
rna
viru
character
spike
protein
project
virion
surfac
protein
contain
two
subunit
subunit
receptor
bind
domain
rbd
interact
host
cell
receptor
angiontensin
convert
enzym
bind
subunit
form
fusion
viru
host
cell
membran
howev
experi
sarscov
shown
proteolyt
action
host
proteas
import
viral
entri
host
cell
bind
host
cell
receptor
first
step
infect
entranc
viru
cell
need
cleavag
subunit
expos
fusion
cell
membran
cellular
proteas
includ
cathepsin
cell
surfac
transmembran
proteaseserin
tmprss
proteas
furin
trypsin
shown
proteolit
process
spike
protein
one
proteas
factor
xa
shown
facilit
activ
sarscov
entri
host
cell
studi
du
l
et
al
sarscov
outbreak
inhibitor
proteas
might
potenti
correspond
cleaveg
protein
candid
supress
infect
screen
result
show
factor
xa
effect
cleav
subunit
sarscov
inhibit
benhcl
inhibitor
seri
proteas
includ
serin
proteas
thrombin
factor
xa
level
cleaveg
factor
xa
infect
target
cell
correl
viral
infect
cleavag
effect
block
benhcl
previous
small
molecul
target
proteas
papain
like
proteas
l
inhibitor
studi
potenti
therapeut
agent
sarscov
among
proteas
furin
highli
express
lung
thought
involv
cleavag
process
recent
articl
point
spike
glycoprotein
contain
furinlik
cleaveg
site
absent
cov
furin
inhibitor
test
new
target
combin
knowledg
mechan
action
unfract
heparin
low
molecular
weight
heparin
inhibitor
sever
proteas
like
factor
xa
thrombin
furin
cathepsinl
hypothes
unfract
heparin
low
molecular
weight
heparin
lmwh
candid
target
proteas
cleavag
cellular
entranc
studi
investig
antifibrot
effect
heparin
shown
heparin
interf
furinlik
proprotein
activ
platelet
latent
transform
growth
factor
apart
use
anticoagul
unfract
heparin
lmwh
shown
poteanti
applic
purpos
allerg
diseas
malign
know
hyperinflamm
macrophag
activ
syndrom
ma
complic
covid
infect
lead
capillari
leakag
acut
respiratori
distress
syndrom
ard
accord
anti
inflammatori
antiprolif
function
usag
unfract
heparin
tinzaparin
dalteparin
benefici
accord
knowledg
sarscov
infect
host
cell
via
proteas
unfract
heparin
lmwh
potenti
inhibitor
multipl
endoproteas
includ
tissu
proteas
matrix
metalloproteinas
cell
signal
inflamm
involv
viru
infect
hypothesi
need
test
vitro
clinic
studi
yet
could
abl
clinic
experinc
pediatr
patient
slight
symptom
mostli
rare
need
intens
care
unit
icu
howev
urgent
situat
burden
increas
around
world
remommend
follow
clinic
usag
heparin
prophylact
use
minidos
heparin
prophylact
dose
lmwh
especi
dalteparin
tinzaparin
use
hospit
nonicu
patient
normal
coagul
profil
normal
platelet
count
order
decreas
viral
load
host
cell
prevent
involv
lower
respiratori
tract
use
minidos
convent
dose
unfract
heparin
prophylact
treatment
dose
lmwh
especi
dalteparin
tinzaparin
use
consider
patient
bleed
thrombot
tendenc
case
dissemin
intravascular
coagul
dic
order
decreas
inflamm
viral
load
lower
respiratori
tract
control
dic
riskbenefit
ratio
use
icu
patient
coagulopathi
judg
clinician
whether
hypothesi
clinic
applic
success
decreas
viral
infect
evalu
studi
none
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
